Pathology EMQ template.

Name: Neeraj Kohli

Candidate number:

Theme: Immune Therapies

OPTION LIST

A	Allergen desensitisation	I	Hepatitis B vaccine
B	Anti-CD3 Ig (OKT3)	J	Hib vaccine
C	Aspirin	K	Human Normal Immunoglobulin
D	Azathioprine	L	Infliximab (anti-TNFalpha)
E	Basilixumab (anti-IL2 receptor Ig)	M	Measles vaccine
F	Bone marrow transplant	N	Rituximab (anti-CD20)
G	Corticosteroid	O	Tacrolimus
H	Cyclophosphamide	P	Tocilizumab (anti-IL6 receptor Ig)

For each scenario below, choose the most appropriate answer from the list above. Each option may be used once, more than once or not at all.

1. Patients with X-linked SCID should not be given this, but may benefit if it is given to their siblings instead.

2. Causes a transient increase in neutrophil count, but a decrease in peripheral lymphocyte count

3. Risk of toxicity in individuals with a polymorphism in the gene for Thiopurine methyltransferase (TPMT)

4. Blocks activation of mature B cells but not plasma cells

5. Post-exposure prophylaxis following Hepatitis B exposure

(Q1: for more details please see www.rcpch.ac.uk/doc.aspx?id_Resource=1768, Section 1, “Immunisation of the Immunocompromised child” Royal College of Paediatrics and Child Health)

ANSWERS

1. M: Measles vaccine

2. G: Corticosteroid

3. D: Azathioprine

4. N: Rituximab (anti-CD20)

5. K: Human Normal Immunoglobulin